Asalkii hore
Daawaynta ku salaysan incretin ayaa muddo dheer la ogaa inay wanaajiso labadabaxakamaynta gulukoosta dhiiggaiyodhimista miisaanka jidhka. Daawooyinka incretin-dhaqameedka ayaa inta badan bartilmaameedsadaGLP-1 receptor, halkaTirzepatidewaxay u taagan tahay jiilka cusub ee "twincretin"Wakiilada - ku dhaqmalabadaba GIP (glucose-ku-tiirsan insulinotropic polypeptide)iyoGLP-1reseptors.
Falkan laba-geesoodka ah ayaa la muujiyay inuu kor u qaadayo faa'iidooyinka dheef-shiid kiimikaadka iyo kor u qaadida miisaan lumis weyn marka loo eego GLP-1 agonists oo keliya.
Naqshadeynta Daraasadda SURMOUNT-1
GURMO-1ahaa arandomized, laba-indho la'aan, wajiga 3 tijaabo caafimaadlaga sameeyay 119 goobood oo sagaal wadan ah.
Ka qaybgalayaasha waxaa ku jiray dad waaweyn oo ahaa:
- Cayil(BMI ≥ 30), ama
- Miisaan badan(BMI ≥ 27) oo leh ugu yaraan hal cudur oo miisaan la xiriira (tusaale, hypertension, dyslipidemia, apnea hurdada, ama cudurada wadnaha iyo xididada).
Shakhsiyaadka qaba sonkorowga, isticmaalka daroogada miisaanka dhimista ee dhowaan, ama qalliinka bariatric ka hor waa laga saaray.
Ka qaybgalayaasha waxaa si aan kala sooc lahayn loo qoondeeyay inay helaan irbado todobaadkiiba mar ah:
- Tirzepatide 5 mg, 10 mg, 15 mg, ama
- Placebo
Dhammaan ka qaybgalayaashu waxay sidoo kale heleen hagidda hab-nololeedka:
- A yaraanta kalooriyada 500 kcal maalintii
- Ugu yaraan150 daqiiqo oo dhaqdhaqaaq jireed todobaadkii
Daawadu way socotay72 todobaad, oo ay ku jiraan a20-usbuuc heerka qiyaasta-kordhintaoo ay ku xigto muddo 52-usbuuc ah oo dayactir ah.
Guudmarka Natiijooyinka
Wadarta guud2,359 ka qaybgalayaashaayaa la qoray.
Celceliska da'da ayaa ahayd44.9 sano, 67.5% waxay ahaayeen haween, oo macne lehmiisaanka jidhka 104.8 kgiyoBMI ee 38.0.
Dhimista celceliska Miisaanka Jirka ee Toddobaadka 72
| Kooxda qiyaasta | % Isbeddelka Miisaanka | Isbeddelka celceliska miisaanka (kg) | Khasaare Dheeraad ah vs Placebo |
|---|---|---|---|
| 5 mg | -15.0% | -16.1 kg | -13.5% |
| 10 mg | -19.5% | -22.2 kg | -18.9% |
| 15 mg | -20.9% | -23.6 kg | -20.1% |
| Placebo | -3.1% | -2.4 kg | - |
Tirzepatide waxay gaadhay 15-21% celcelis ahaan dhimista miisaanka jidhka, muujinaya saameyn cad oo ku-tiirsanaanta qiyaasta.
Boqolkiiba ka qaybqaatayaasha Gaadhida Himilada Yoominta
| Miisaanka dhimista (%) | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| ≥5% | 85.1% | 88.9% | 90.9% | 34.5% |
| ≥10% | 68.5% | 78.1% | 83.5% | 18.8% |
| ≥15% | 48.0% | 66.6% | 70.6% | 8.8% |
| ≥20% | 30.0% | 50.1% | 56.7% | 3.1% |
| ≥25% | 15.3% | 32.3% | 36.2% | 1.5% |
In ka badan kala badhka qaybgalayaasha helaya≥10 mgTirzepatide waa la gaaray≥20% miisaanka oo yaraada, ku soo dhawaada saamaynta lagu arkay qaliinka bariatric.
Faa'iidooyinka dheef-shiid kiimikaadka iyo xididdada wadnaha
Marka la barbar dhigo placebo, Tirzepatide si weyn ayay u horumartay:
- Wareegga dhexda
- Cadaadiska dhiigga ee Systolic
- profile Lipid
- Heerarka insulin ee soonka
Ka mid ah ka qaybgalayaasha lehcudurka macaanka, 95.3% waxay ku noqdeen heerarka gulukoosta caadiga ah, marka loo eego61.9%Kooxda placebo - oo tilmaamaysa Tirzepatide kaliya maaha inay caawiso dhimista miisaanka laakiin sidoo kale waxay wanaajisaa dheef-shiid kiimikaadka gulukooska.
Badbaadada iyo Dulqaadashada
Waxyeellooyinka ugu badan ee soo raaca waxay ahaayeencaloosha iyo mindhicirka, oo ay ku jiraanlalabo, shuban, iyo calool istaag, inta badan khafiif ah oo ku meel gaadh ah.
Heerka joojinta dhacdooyinka xun dartood waxay ahayd qiyaastii4-7%.
Dhimasho yar ayaa dhacay intii ay socotay tijaabada, oo ugu horayn lala xiriiriyayCOVID 19, oo aan si toos ah ula xiriirin daroogada daraasadda.
Ma jiro farqi weyn oo lagu arkay dhibaatooyinka la xiriira xameetida.
Dood
Beddelka hab-nololeedka oo keliya (cuntada iyo jimicsiga) ayaa caadi ahaan soo saara oo keliya~ 3% celceliska miisaanka oo yaraada, sida lagu arkay kooxda placebo.
Taas bedelkeeda, Tirzepatide waa la furay15-21% wadarta dhimista miisaanka jidhka, oo matalaya a5-7 jeer saameyn weyn.
Marka la barbar dhigo:
- Daawooyinka miisaanka afka laga qaato:badiyaa waxay gaadhaan 5-10% khasaare
- Qalliinka Bariatricgaadho>20% khasaare
Tirzepatide waxay isku xidhaa farqiga u dhexeeya farmashiilojiga iyo waxqabadyada qalliinka - bixintaawood leh, hoos u dhigista miisaanka.
Muhiimad ahaan, welwelka ku saabsan dheef-shiid kiimikaadka gulukooska ee sii xumaanaya lama arag. Taas beddelkeeda, Tirzepatide waxay wanaajisay dareenka insulinta waxayna beddeshay cudurka macaanka ee ka qaybgalayaasha intooda badan.
Si kastaba ha ahaatee, tijaabadani waxay barbardhigtay Tirzepatide iyo placebo - si toos ah ulama ekaSemaglutide.
Isbarbardhigga madax-ilaa-madaxa ayaa loo baahan yahay si loo go'aamiyo wakiilka soo saara miisaan weyn.
Gabagabo
Dadka qaangaarka ah ee leh buurnaanta ama cayilka iyo cudurrada la xiriira, ku darTirzepatide-isbuucii hal marbarnaamijka qaab nololeedka habaysan (cuntada + jimicsiga) waxay u horseedi kartaa:
- 15-21% celcelis ahaan dhimista miisaanka jidhka
- Horumarin dheef-shiid kiimikaad oo muhiim ah
- Dulqaad sare iyo badbaado
Tirzepatide sidaas darteed waxay u taagan tahay daaweyn wax ku ool ah oo caafimaad ahaan la ansaxiyay oo loogu talagalay waara, maaraynta miisaan caafimaad ahaan la kormeero.
Waqtiga boostada: Oct-16-2025